Tag Archives: NDMM

EMA Committee Recommends Approval of Sarclisa-VRd Induction in Newly Diagnosed Multiple Myeloma Patients Eligible for Transplant

(IN BRIEF) The CHMP has recommended EU approval of Sarclisa alongside VRd for transplant-eligible NDMM, based on GMMG-HD7 trial results showing superior MRD negativity and PFS compared to VRd alone. This potential label extension would mark Sarclisa’s fourth EU approval … Read the full press release

Sanofi’s Sarclisa Becomes First Anti-CD38 Therapy Approved in the EU for Front-Line Treatment of Transplant-Ineligible Multiple Myeloma

(IN BRIEF) Sanofi’s Sarclisa has been approved by the European Union as the first anti-CD38 therapy in combination with VRd to treat adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. This approval is … Read the full press release